Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals is a U.S. biopharmaceutical company focused on developing and commercializing medicines for rare blood disorders. Its science builds on cellular metabolism and related disease pathways, seeking targeted therapeutic approaches for inherited hematologic conditions. The company's development activities combine clinical research, regulatory work and commercialization of prescription medicines. Agios is based in Cambridge, Massachusetts, and is listed on Nasdaq under AGIO. This company directory records the issuer's core therapeutic specialization, rather than offering a complete record of individual treatment indications, regulatory decisions or quarterly performance.
Company at a glance
Corporate information
- Company entity
- Agios Pharmaceuticals, Inc.
- Headquarters / principal office
- United States
- Founded
- Not verified
- Ownership / capital status
- Publicly tradedPublicly listed
- Official corporate reference
- https://www.agios.com/
- LinkedIn company page
- Independent company page not verified
Profile review: 2026-11-08 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Listed issuer and R&D focus
Nasdaq: AGIO
cellular metabolism · targeted small molecules
rare hematologic diseases
Last independently verified:
Disease tags match recorded text mentions and require program-level verification.
Technology, programs & evidence
Agios Pharmaceuticals is a U.S. biopharmaceutical company focused on developing and commercializing medicines for rare blood disorders. Its science builds on cellular metabolism and related disease pathways, seeking targeted therapeutic approaches for inherited hematologic conditions. The company's development activities combine clinical research, regulatory work and commercialization of prescription medicines. Agios is based in Cambridge, Massachusetts, and is listed on Nasdaq under AGIO. This company directory records the issuer's core therapeutic specialization, rather than offering a complete record of individual treatment indications, regulatory decisions or quarterly performance.
Business, technology & evidence
- SecuritiesNasdaq: AGIO
Individual program detail is not recorded. Consult the original sources below.
Related news & literature
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
Showing 0 / 0 related items
No cataloged update explicitly mentions this company.
Same-field reading (not company-specific)
Research this company together
Discussions are for signed-in members. Personal notes remain separate from company research.
Sign in to joinSources & open questions
- Official issuer and R&D disclosure · Agios Pharmaceuticals, Inc. ↗Agios Pharmaceuticals, Inc. ·
- Official issuer and R&D disclosure · Agios Pharmaceuticals, Inc. ↗Agios Pharmaceuticals, Inc. ·
Inclusion is not endorsement or partner qualification. Assess company claims, clinical evidence, and project-specific capabilities separately.